Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2023-08-01
2023-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question it aims to answer is there a relationship between saliva sTREM-1, sTREM-2, Presepsin levels, sTREM-1/sTREM-2 ratio and periodontitis.
Participants will give saliva samples without any intervention
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Salivary Biomarker Levels in Individuals With Various Periodontal Diseases
NCT07025291
Salivary Proteome in Response to Non-surgical Periodontal Treatment
NCT05952895
Evaluation of Salivary Adseverin, 1-Alpha Defensin and sRANKL Levels of Individuals With Different Periodontal Diseases
NCT06402877
Evaluation of Trimethylamine N-oxide (TMAO) Levels in Periodontal Disease
NCT06906510
Periodontal Disease and Salivary Mitofusin Levels
NCT06510608
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
sTREM-1, the soluble form of TREM-1 resulting from the cleavage by MMP (matrix metalloproteinase) of the extracellular portion of this receptor, was identified in 2004. Higher concentrations of sTREM-1 were noted in gingival crevicular fluid (GCF) and saliva from patients with periodontitis and correlated with certain periodontal clinical parameters (Plaque Index \[PlI\], Gingival Index \[GI\], PPD or clinical attachment loss \[CAL\]). TREM-2, another member of the TREM family, is also synthesised by macrophages and together with its receptor, DNAX-activating protein of 12 kDa (DAP12), functions to suppress the proinflammatory response. Initial studies with TREM-2 in microglia cells showed that it plays an important role in suppressing TNF-α and IL-6 levels. The secretion of presepsin has been reported as a stimulus of monocytes phagocytosis. Therefore, recognition of presepsin is predictable even in healthy non-infective individuals. The concept for presepsin proposes that its levels should be measureable in non-infective individuals, increase the early steps of bacterial infections, and its levels should be dependent on the intensity of the innate immune induction.
The study material will be 70 adult individuals who applied to Atatürk University Faculty of Dentistry, Department of Periodontology for different reasons {1. group (H): periodontally healthy individuals, group 2 (P): individuals with periodontitis}. Saliva samples will be collected from the participants without any periodontal intervention. sTREM-1, sTREM-2, Presepsin levels will be studied.
The aim of this study; to evaluate the saliva sTREM-1, sTREM-2, Presepsin levels and sTREM-1/sTREM-2 ratio in the saliva samples of patients with periodontitis by comparing them with healthy controls, and to investigate the association in the pathogenesis of periodontitis or a simple marker of disease activity in the light of these findings.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy
participants without periodontitis
no intervention
no intervention
periodontitis
participants with stage-3 periodontitis
no intervention
no intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
no intervention
no intervention
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals have not been continuously treated with anti-inflammatory, antioxidant or similar drugs in the last 6 months,
* Individuals have not received periodontal treatment until 6 months ago,
* Individuals must have at least 14 teeth
* Patients diagnosed with stage 3 periodontitis
Exclusion Criteria
* Being pregnant/breastfeeding
* Being on medication for any reason
* Being a smoker/tobacco user
* Having another periodontal disease other than periodontitis
* Having a chronic inflammatory disease (COPD, asthma)
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ataturk University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Didem OZKAL EMINOGLU
assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
DİDEM ÖZKAL EMİNOĞLU
Role: STUDY_DIRECTOR
Ataturk University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Atatürk University
Erzurum, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
atauniperio3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.